SSTR2 and hepatocellular carcinoma: While the role of SSTR2 in mediating resistance to sorafenib in HCC remains to be elucidated, SSTR2-targeted theranostic applications have significant potential to synergize with sorafenib and improve its efficacy in sorafenib-resistant SSTR2-positive cases.